First mRNA‑based flu vaccine wins US approval, Moderna’s Ebola candidate reaches the clinic, and early‑phase cancer vaccine trials broaden across personalized and off‑the‑shelf platforms

The US FDA approved the first mRNA-based influenza vaccine, clearing the way for messenger RNA technology to move into a second major indication beyond COVID-19, while Moderna dosed the first participants in its own mRNA candidate against Bundibugyo ebolavirus as the outbreak in the Democratic Republic of the Congo continued. Mpox vaccine access widened to children as young as two in the European Union, a six-valent Lyme disease vaccine advanced toward EU review, and a cluster of early-phase trials opened for personalized and off-the-shelf cancer vaccine candidates spanning lung, breast, esophagogastric, and pancreatic cancer.

Preparing paper insights from the available abstract and paper details.

Authors

Ashling Cannon

Published

Sep 10, 2026

Journal or venue

Vaccine Insights

DOI

10.18609/vac.2026.048

Paper type

journal article

Source

Crossref